Koyfin Home > Directory > Health Care > Antares Pharma > EBIT

Antares Pharma EBIT Chart (ATRS)

Antares Pharma annual/quarterly EBIT from 2000 to 2018. Earnings before interest and taxes measures the profit a company generates from its operations, making it synonymous with operating profit. By ignoring tax and interest expenses, it focuses solely on a company's ability to generate earnings from operations, ignoring variables such as the tax burden and capital structure.
  • Antares Pharma EBIT for the quarter ending December 12, 2018 was $-6m a 1.63% decrease of 0m year over year
  • Antares Pharma EBIT for the last 12 months ending December 12, 2018 was $-17m a -4.23% increase of 1m year over year
  • Antares Pharma Annual EBIT for 2018 was $-17m a 0.90% decrease of 0m from 2017
  • Antares Pharma Annual EBIT for 2017 was $-16m a -46.60% increase of 8m from 2016
  • Antares Pharma Annual EBIT for 2016 was $-24m a 15.16% decrease of -4m from 2015
Other Income Statement Metrics:
  • Antares Pharma EBITDA for the quarter ending December 12, 2018 was $-5m a 1.88% decrease of 0m year over year
  • Antares Pharma Net Income for the quarter ending December 12, 2018 was $6m a 200.96% increase of 12m year over year
  • Antares Pharma Total Revenue for the quarter ending December 12, 2018 was $19m a 32.51% increase of 6m year over year
View Chart On Koyfin

Quarterly ATRS EBIT Data

12/2018$-6m
09/2018$-1m
06/2018$-4m
03/2018$-6m
12/2017$-4m
09/2017$-5m
06/2017$-3m
03/2017$-5m
12/2016$-4m
09/2016$-6m

Annual ATRS EBIT Data

2018$-17m
2017$-16m
2016$-24m
2015$-20m
2014$-35m
2013$-21m
2012$-11m
2011$-4m
2010$-6m
2009$-10m